Aclaris Therapeutics Inc (ACRS)
15.12
-0.58 -3.69%
NASDAQ
Jul 26, 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 6.852M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -1.40 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -64.18M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 32.36% |
| Profit Margin (Quarterly) | -1.62K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 894.34M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 98.68 |
| PE Ratio | -- |
| Price to Book Value | 7.964 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.0952 |
| Free Cash Flow (Quarterly) | -12.23M |
| Return on Equity | Upgrade |
View All ACRS News
News
-
WireHeadlineTime (ET)
-
SA Breaking News07/23 15:37
-
Globe Newswire07/08 07:00
-
Yahoo07/06 11:49
-
Yahoo07/06 10:13
-
MT Newswires06/16 06:45
-
MT Newswires06/15 06:28
-
MT Newswires06/10 09:09
-
MT Newswires06/10 04:41
-
SA Breaking News06/10 00:29
-
Globe Newswire06/09 19:55
-
SA Breaking News06/09 13:46
-
SA Breaking News06/09 11:07
-
Yahoo06/09 11:00
-
MT Newswires06/08 16:32
-
Globe Newswire06/08 16:15
-
Yahoo06/08 15:16
-
SA Breaking News06/08 11:02
-
MT Newswires06/08 09:48
-
Yahoo06/08 07:46
-
Globe Newswire06/08 07:00
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 11/04/2021 17:00 EST | Earnings Calls | Q3 2021 Earnings Call |
| 08/06/2021 | Earnings Results | Q2 2021 Earnings Results |
| 06/03/2021 09:00 EST | AGM | 2020 Annual General Meeting |
| 05/07/2021 | Earnings Results | Q1 2021 Earnings Results |
| 02/25/2021 | Earnings Results | Q4 2020 Earnings Results |
| 11/04/2020 | Earnings Results | Q3 2020 Earnings Results |
| 08/07/2020 | Earnings Results | Q2 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are ATI-450, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
- URL: https://www.aclaristx.com
- Investor Relations URL: https://www.aclaristx.com/#!investors/juser
- HQ State/Province: Pennsylvania
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Growth
- Next Earnings Release: Aug. 06, 2021
- Last Earnings Release: May. 07, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 15.12 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| BRSIX | Bridgeway Ultra-Small Company Market | 1.46% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ACRS Tweets Stocktwits
Advertisement
